Proteomic Markers of Alcohol Abuse (Phase 1)

酒精滥用的蛋白质组标记（第一阶段）

• 批准号: 7119567
• 负责人: LAWRENCE DOUGLAS SNELL
• 金额: $ 47.55万
• 依托单位: LOHOCLA RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7119567
• 关键词: alcoholic beverage consumption; alcoholism /alcohol abuse; amine oxidase (flavin); biomarker; biotechnology; blood chemistry; clinical research; computer program /software; diagnosis quality /standard; enzyme activity; enzyme linked immunosorbent assay; high performance liquid chromatography; human data; mass spectrometry; measurement; method development; protein glutamine gamma glutamyltransferase; protein quantitation /detection; protein structure; proteomics; serology /serodiagnosis

DESCRIPTION (provided by applicant): Alcohol dependence and hazardous levels of ethanol ingestion are under-diagnosed and under-reported. Significant effort has been expended to develop biological markers (diagnostics) for monitoring levels and/or recency of alcohol use (state markers) and markers for predisposition to alcohol dependence (trait, "etiologic", markers). However, this area of research has not yet generated unequivocal tools to be used by treatment and prevention specialists and others interested in such information. A new era in science emerged with the detailed knowledge of the human genome and the human proteome is now being defined. The power of proteomic techniques and informatics technology is ready to be applied to the search for better (more reliable) diagnostic tools for hazardous alcohol use and alcoholism. Lohocla Research Corporation has access to biological samples (plasma, serum and platelets) from over 1,000 individuals who are well characterized with regards to drinking habits, medical/psychiatric disorders, family history of medical/psychiatric disorders, drug use, etc. Lohocla will partner with Eprogen, the developers of the ProteoSep TM proteomic technology, to discover and test a novel panel of diagnostics for alcohol use, abuse and alcoholism. Phase I studies, will test the feasibility of using ProteoSep TM technology to identify and quantitate proteins already known to be altered by alcohol intake/alcoholism and to identify novel candidate markers. We will establish proteomic methodology (ProteoSep TM) to accurately measure currently used state markers for excessive alcohol ingestion (GGT, AST and CDT) in plasma and serum samples and develop a measurement, with ProteoSep TM technology, of MAO-B protein in platelet samples. A panel of bioinformatic/statistical tools will be applied to search for new markers. If we are able to successfully measure the levels of proteins such as GGT, AST, CDT and MAO, these proteins will form "internal standards" against which other novel marker proteins can be tested in Phase II. Phase I studies will also provide the initial panel of candidate markers to be assessed in a significantly greater number of subjects in Phase ll.

描述（由申请人提供）：酒精依赖性和乙醇摄入的危险水平不足和报告不足。已经花费了巨大的努力来开发用于监测酒精使用水平和/或重新度（状态标记）的生物标记物（诊断）和易感性依赖性的标志物（特质，“病因学”，标记）。但是，这一研究领域尚未生成明确的工具，可以被治疗和预防专家以及对此类信息感兴趣的其他人使用。 现在已经定义了有关人类基因组和人类蛋白质组的详细知识的科学新时代。蛋白质组学技术和信息学技术的力量已准备好用于寻找更好（更可靠的）诊断工具，以造成危险的酒精使用和酒精中毒。 Lohocla Research Corporation可以从1,000多个人获得生物学样本（血浆，血清和血小板），这些人在饮酒习惯，医学/精神病患者，医学/精神疾病的家族史，药物使用，药物使用等方面都有良好的特征。虐待和酗酒。 第一阶段的研究将测试使用蛋白质TM技术来识别和定量已知已被酒精摄入/酒精中毒改变并鉴定新型候选标记的蛋白质的可行性。我们将建立蛋白质组学方法论（蛋白质蛋白酶TM），以准确测量血浆和血清样品中过量饮酒（GGT，AST和CDT）的状态标记物，并通过蛋白质蛋白质TM技术，Platelet样品中MAO-B蛋白的蛋白质TM技术进行测量。将应用一组生物信息学/统计工具来搜索新标记。 如果我们能够成功地测量GGT，AST，CDT和MAO等蛋白质的水平，那么这些蛋白质将形成“内部标准”，可以在II期中对其他新型标记蛋白进行测试。第一阶段的研究还将提供候选标记的初始面板，以在LL期间显着评估。